Palopegteriparatide
Also known as: AZP-3601, peg-PTH(1-34), TransCon PTH, Yorvipath
Source Palopegteriparatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Palopegteriparatide (brand name Yorvipath) is a long-acting, PEGylated prodrug of teriparatide approved for the treatment of chronic hypoparathyroidism in adults. It provides a sustained delivery of PTH(1-34) to mimic physiological parathyroid hormone activity, reducing dependence on calcium and active vitamin D supplementation.
Mechanism of Action
Palopegteriparatide is a PEGylated prodrug of teriparatide (PTH 1-34) that acts as a full agonist at the parathyroid hormone type 1 receptor (PTH1R). Upon subcutaneous administration, the PEG moiety is cleaved to release active teriparatide, activating PTH1R on osteoblasts and renal tubular cells, stimulating bone formation and regulating calcium and phosphate homeostasis. Designed to provide sustained, near-physiologic PTH exposure for hypoparathyroidism.
Routes of Administration
Goals & Uses
- Normalization of serum calcium levelsEndocrine/MetabolicHigh
- Improvement of quality of life in hypoparathyroidismPatient Reported OutcomesModerate
- Reduction of calcium and vitamin D supplementation burdenEndocrine/MetabolicHigh
- Reduction of hypercalciuria and renal complicationsRenalModerate
- Treatment of chronic hypoparathyroidismEndocrine/MetabolicHigh
Contraindications
- Osteosarcoma risk conditions (Paget's disease, prior radiation therapy to skeleton)OncologicHigh
- Hypersensitivity to teriparatide or PEG componentsAllergy/ImmunologicHigh
- HypercalcemiaMetabolic DisorderHigh
- Pediatric patients with open epiphysesPediatricHigh
- Metabolic bone diseases other than hypoparathyroidismMusculoskeletalModerate
Adverse Effects
- HypercalcemiaMetabolicCommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypercalciuriaMetabolicUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- HypocalcemiaMetabolicCommon
Drug Interactions
- BisphosphonatesLow
- Active vitamin D analogs (calcitriol, alfacalcidol)Moderate
- Calcium supplementsModerate
- Thiazide diureticsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- History of nephrolithiasis or nephrocalcinosisRenalRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeAbsolute
- BreastfeedingReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Chronic hypoparathyroidism in adultsEMA approved in 2023 under the brand name Yorvipath. Designated as an orphan medicinal product.
- United StatesApprovedApproved: Chronic hypoparathyroidism in adultsFDA approved in 2024 under the brand name Yorvipath. Received Orphan Drug Designation.
- United KingdomApprovedApproved: Chronic hypoparathyroidism in adultsApproved by MHRA following EMA authorization; available as Yorvipath.
Approved by the EMA in 2023 for adults with chronic hypoparathyroidism. FDA approved in 2024 under the brand name Yorvipath for the same indication. Developed by Ascendis Pharma using their TransCon technology platform.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Palopegteriparatide?
Palopegteriparatide (brand name Yorvipath) is a long-acting, PEGylated prodrug of teriparatide approved for the treatment of chronic hypoparathyroidism in adults. It provides a sustained delivery of PTH(1-34) to mimic physiological parathyroid hormone activity, reducing dependence on calcium and active vitamin D supplementation.
What is Palopegteriparatide used for?
Palopegteriparatide is educationally associated with: Normalization of serum calcium levels, Improvement of quality of life in hypoparathyroidism, Reduction of calcium and vitamin D supplementation burden, Reduction of hypercalciuria and renal complications, Treatment of chronic hypoparathyroidism. Educational only — not medical advice.
How is Palopegteriparatide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Palopegteriparatide?
Reported adverse effects include: Hypercalcemia, Injection site reactions, Headache, Hypercalciuria, Nausea, Hypocalcemia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Palopegteriparatide?
Recorded contraindications: Osteosarcoma risk conditions (Paget's disease, prior radiation therapy to skeleton), Hypersensitivity to teriparatide or PEG components, Hypercalcemia, Pediatric patients with open epiphyses, Metabolic bone diseases other than hypoparathyroidism. Consult a qualified clinician before use.